Navigation Links
Statin Might Help Fight Blood Clots in Veins
Date:3/29/2009

Cholesterol-lowering Crestor cut risk by 43 percent, study found

SUNDAY, March 29 (HealthDay News) -- In addition to dramatically reducing the incidence of heart attacks and stroke, the cholesterol-lowering drug Crestor appears to have another important benefit: reducing the rate of blood clots in the veins, new research has found.

Interestingly, participants in this study, being presented Sunday at the American College of Cardiology annual meeting in Orlando, Fla., did not have elevated levels of LDL, or "bad," cholesterol, but they did have increased levels of the inflammatory marker called C-reactive protein (CRP).

"This suggests that a statin has potential beneficial effects on the venous circulation, not just the arterial circulation," said Dr. Carl J. Lavie, medical director of cardiac rehabilitation at the Ochsner Heart and Vascular Institute in New Orleans.

Lavie, who was not involved with the study, cautioned, however, that "this data is probably not powerful enough to use statins just for this reason."

The findings also suggest that statins may derive some of their benefit from their effect on C-reactive protein.

In fact, another study, also being presented at the meeting, concluded that, besides lowering cholesterol, part of the success of statins in reducing cardiovascular events such as a heart attack can be attributed to the lowering levels of CRP.

Both studies are based on data from the landmark JUPITER trial, sponsored by the drug maker AstraZeneca, which markets Crestor (rosuvastatin). The first trial is being published early in the April 30 issue of the New England Journal of Medicine, while the second will appear in an upcoming issue of The Lancet.

For the JUPITER trial, nearly 18,000 men and women, average age 66, were randomly assigned to receive 20 milligrams of Crestor daily or a placebo. All the participants were "apparently healthy," with LDL cholesterol levels under 130 milligrams per deciliter of blood, and high-sensitivity C-reactive protein levels of 2 mg/liter or higher (slightly elevated). Just over a third of the participants were obese.

After a median follow-up of almost two years, Crestor was found to reduce the risk of blood clots in the veins (venous thromboembolism) by 43 percent compared to a placebo. The risk reduction was seen both in those without risk factors and those with risk factors for clots, such as people who were hospitalized, had cancer or who had undergone surgery, the study found.

There was no elevated risk of bleeding in people taking Crestor.

"We're very pleased that the drug seems to have this beneficial effect," said study author Robert J. Glynn, a biostatistician in the division of preventive medicine at Brigham and Women's Hospital in Boston. He added that the effect would probably also be seen in other statins.

The second trial found that participants who had reductions in both LDL and CRP levels had a reduction in vascular events that ranged from 65 percent to 79 percent.

The JUPITER trial was halted early last year when researchers noted a 44 percent reduction in the risk of heart attack and stroke in the Crestor group.

The mechanisms by which statins lower clot risk aren't well understood, although some experts suspect the lowering of CRP may explain the decline.

"High CRP also has been a risk factor for developing arterial disease, and maybe the same now holds true for venous disease," Lavie said. "It supports the notion that cholesterol and/or CRP play a role in venous thromboembolic disease as well as arterial disease, and that statins appear to play a beneficial role in this as well."

Experts estimated that the original findings from the JUPITER trial -- that Crestor reduced the risk of heart attacks and stroke by 44 percent -- might add 11 million people to the already large population of older Americans taking statins.

So does this mean everyone will eventually be on statins to guard their heart health?

"It's an expensive drug [and] it's always wrong to say take a pill and don't deal with your life. People need to exercise and change their diet," Glynn stressed.

More information

The U.S. National Library of Medicine has more on blood clots.



SOURCES: Robert J. Glynn, Sc.D., biostatistician, division of preventive medicine, Brigham and Women's Hospital, and associate professor, medicine, Harvard Medical School, Boston; Carl J. Lavie, M.D., medical director, cardiac rehabilitation and prevention, and director, Stress Testing Laboratory, Ochsner Heart and Vascular Institute, New Orleans; March 29, 2009, presentation, American College of Cardiology annual meeting, Orlando, Fla.; April 30, 2009, New England Journal of Medicine; The Lancet


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Finds Millions More May Benefit From Statins
2. 6.5 million more patients might benefit from statins to prevent heart attacks, strokes
3. Global War on Drugs Takes Devastating Toll on Human Lives, Advocates Say
4. Statins lower stroke severity, improve recovery
5. Dallas Scientists Discover Statins May Falsely Indicate Thyroid Problems
6. Statins Pay Off on a Health-Policy Level, UCSF Study Finds
7. Not Many U.S. Kids Need Statins
8. Taking Statins Faithfully Lengthens Life
9. Statins Dont Cut Cancer Risk
10. Got High Cholesterol? Statins Are Not the Only Answer, Says Natural Solutions Magazine
11. Following Ceremony with President Obama, UAN President Ann Converso, RN, Commends New Administration on Meeting with Labor Leaders and Reinstating Pro-Worker Policies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Statin Might Help Fight Blood Clots in Veins
(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the United ... persecution, Center for Medicine after the Holocaust (CMATH) announced that it will ... and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany and ...
(Date:4/24/2017)... ... , ... Today, Bright Pink , a national non-profit organization focusing on the prevention and ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive Officer. ... as Chairman of the Board and launched a national search to find a visionary ...
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke to the ... life forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, when her ... I began journaling conversations and situations throughout my divorce,” James said. “After the death ...
(Date:4/24/2017)... ... 2017 , ... The world-class designers of Happy Gadget Alert ... lifesaving device for the everyday use of parents worldwide. It is a lightweight, ... a child’s vital signs, and detect unusual symptoms or physical patterns. This innovative ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology: